Pterostilbene

Pharmacology & Research

Pterostilbene is a dimethylated stilbenoid — the 3,5-dimethyl ether of resveratrol — found chiefly in blueberries, and it is sold as a longevity and metabolic-support nootropic. Its two methoxy groups make it markedly more lipophilic and metabolically stable than resveratrol, which is the whole reason it exists as a distinct supplement: it gets absorbed and stays around, where resveratrol largely does not. The catch is that most of what is claimed for it rests on cell and rodent work; the human trial base is small, and several of the best-known human studies actually tested pterostilbene combined with nicotinamide riboside (the “Basis”/NRPT formula), which makes it hard to credit any effect to pterostilbene alone. The one clean human efficacy signal — a modest blood-pressure drop — came alongside an unwanted rise in LDL cholesterol, so the honest read is “promising bioavailability, thin and mixed human outcomes.”

1. Blood pressure

In the only dedicated human efficacy trial — a randomised, double-blind, placebo-controlled study of 80 adults with elevated cholesterol — high-dose pterostilbene (125 mg twice daily) lowered both systolic (−7.8 mmHg) and diastolic (−7.3 mmHg) blood pressure over 6–8 weeks ^{1Reference 1Riche et al. · 2014RCTAnalysis of pterostilbene on metabolic parameters: a randomized, double-blind, and placebo-controlled trial — [RCT]View study →}. This is a genuine, clinically meaningful effect and the strongest human result the compound has. It is tempered by being a single trial in a specific (hypercholesterolemic) population, and by the same trial showing an unwanted LDL increase on monotherapy.

Gap: never independently replicated, and the population was not normotensive-healthy, so generalisation to blood-pressure lowering in the general public is unproven.

2. Liver / NAFLD markers

A 6-month RCT in 111 adults with non-alcoholic fatty liver disease tested NRPT (nicotinamide riboside + pterostilbene, marketed as Basis) ^{3Reference 3Dellinger et al. · 2023RCTNicotinamide riboside and pterostilbene reduces markers of hepatic inflammation in NAFLD: a double-blind, placebo-controlled clinical trial — [RCT]View study →}. The primary endpoint — hepatic fat fraction — did not change versus placebo. However, the standard-dose group showed a significant, time-dependent fall in the liver enzymes ALT and GGT and in a toxic ceramide, with no dose-dependence (the double dose did not do better). The signal is toward reduced hepatic inflammation, not reduced liver fat.

Gap: pterostilbene was co-administered with nicotinamide riboside, so no effect can be attributed to pterostilbene alone, and the headline liver-fat outcome was null.

3. Glucose & metabolic regulation

Mechanistically, pterostilbene activates AMPK and suppresses hepatic gluconeogenic gene expression (PEPCK, G6Pase) in liver cells ^{11Reference 11Ren et al. · 2018In vitroAMPK activation by pterostilbene contributes to suppression of hepatic gluconeogenic gene expression and glucose production — [in vitro]View study →}, and in streptozotocin-diabetic rats it lowered blood glucose and glycated haemoglobin and shifted glucose-metabolising enzymes, with effects compared to metformin ^{10Reference 10Pari et al. · 2006AnimalEffect of pterostilbene on hepatic key enzymes of glucose metabolism in streptozotocin- and nicotinamide-induced diabetic rats — [animal]View study →}. In humans, the metabolic trial noted only minor weight loss (−0.62 kg/m²) in participants not on cholesterol medication, and no dedicated glycaemic outcome ^{1Reference 1Riche et al. · 2014RCTAnalysis of pterostilbene on metabolic parameters: a randomized, double-blind, and placebo-controlled trial — [RCT]View study →}.

Gap: the antidiabetic data are almost entirely rodent and in-vitro; there is no human trial with a glucose or HbA1c primary endpoint.

4. Cognition & neuroprotection

Chronic pterostilbene improved cognitive performance in 18-month-old rats with mild cognitive impairment ^{15Reference 15La Spina et al. · 2019AnimalPterostilbene improves cognitive performance in aged rats: an in vivo study — [animal]View study →}, and in Alzheimer’s-model (APP/PS1) mice it reduced amyloid-β toxicity and rescued dendritic-spine density via a PDE4A–CREB–BDNF mechanism ^{16Reference 16Meng et al. · 2019Pterostilbene attenuates amyloid-β-induced neurotoxicity by regulating the PDE4A-CREB-BDNF pathway — [animal]View study →}. The plausible edge over resveratrol is pharmacokinetic: intact pterostilbene reaches the brain, where it predominates over its sulfate metabolite ^{8Reference 8Azzolini et al. · 2014AnimalPharmacokinetics and tissue distribution of pterostilbene in the rat — [animal PK]View study →}. That said, all efficacy evidence here is preclinical.

Gap: no human cognitive trial exists; the “nootropic” label is mechanistic and animal-based inference, not demonstrated benefit in people.

5. Cancer chemoprevention

Pterostilbene shows broad anti-proliferative and pro-apoptotic activity across cultured tumour lines, and in a transgenic mouse model of MTA1-driven premalignant prostate disease, dietary pterostilbene intercepted progression ^{17Reference 17Hemani et al. · 2022Dietary pterostilbene for MTA1-targeted interception in high-risk premalignant prostate cancer — [animal]View study →}. This is chemoprevention-relevant preclinical work, not treatment data.

Gap: there is no human oncology efficacy trial; a registered prostate-cancer combination study exists but the evidence base remains cell- and mouse-level.

Mechanisms

Target / pathway	Effect	Relevant to
SIRT1	Activation (sirtuin agonism)	Longevity, metabolic, neuroprotection
AMPK	Activation → ↓ hepatic gluconeogenesis, ↑ fatty-acid oxidation	Glucose, liver, metabolic
Nrf2 / HO-1 antioxidant axis	Upregulation of SOD, CAT, GPx, phase-II enzymes	Antioxidant, liver protection
PPAR-α	Agonism → ↑ ACO, CPT-1	Lipid oxidation, metabolic
PDE4A–CREB–BDNF	Modulation (preclinical)	Cognition, neuroprotection

Pharmacokinetics

Pharmacokinetics is the decision-relevant part of the pterostilbene story. The two methoxy groups replace hydroxyls that resveratrol loses rapidly to glucuronidation and sulfation, so pterostilbene resists first-pass conjugation and is more lipophilic. In rats given equimolar oral doses, pterostilbene reached far higher and longer-lasting plasma levels than resveratrol ^{7Reference 7Kapetanovic et al. · 2011AnimalPharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats — [animal PK]View study →}. Oral bioavailability is moderate (~35% in rat) with an intravenous half-life near 1.8 hours; the major circulating species is pterostilbene-4′-sulfate, but tissue exposure runs 2- to 25-fold above blood, and — importantly for the neuro claims — intact (unconjugated) pterostilbene predominates in the brain ^{8Reference 8Azzolini et al. · 2014AnimalPharmacokinetics and tissue distribution of pterostilbene in the rat — [animal PK]View study →}. Human pharmacokinetic characterisation is limited and much of the quantitative data is rodent ^{9Reference 9Wang et al. · 2018ReviewMetabolism and pharmacokinetics of resveratrol and pterostilbene — [review]View study →}; newer cocrystal formulations are being trialled specifically to raise human exposure.

Clinical trials

Registered human activity is modest and dominated by the nicotinamide-riboside combination product (Basis/NRPT/EH301) rather than pterostilbene alone; standalone pterostilbene trials are mostly small safety, bioavailability, or single-outcome studies. As an off-patent natural compound, it attracts little large-scale industry efficacy investment.

Last checked: July 2026.

Dietary Sources

Pterostilbene is a phytoalexin — a compound plants make under stress — and dietary amounts are small. Blueberries are the best-known food source, with grapes, some other berries, and peanuts contributing lesser amounts; the compound is also present in the heartwood of Pterocarpus marsupium (Indian kino), the traditional-medicine source from which it was first characterised.

Food source	Relative pterostilbene content	Notes
Blueberries	Highest common dietary source	Content varies widely by cultivar, ripeness and growing conditions
Grapes / grape products	Low–moderate	Alongside resveratrol; concentrated in skin
Peanuts	Low	Present but minor
Pterocarpus marsupium heartwood	High (non-food botanical)	Historical/traditional source, used in some extracts

The practical point: even blueberry-rich diets deliver on the order of a few milligrams at most, whereas studied supplemental doses are 50–250 mg — so the food supply is nowhere near the amounts tested in trials. Supplemental pterostilbene is manufactured (synthesised or produced biotechnologically) for this reason ^{12,13Reference 12Nagarajan et al. · 2022ReviewNew insights into dietary pterostilbene: sources, metabolism, and health promotion effects — [review]View study →Reference 13Lin et al. · 2020ReviewOccurrence, bioavailability, anti-inflammatory, and anticancer effects of pterostilbene — [review]View study →}.

Dosage & Intake

Pterostilbene is not an essential nutrient, so there is no RDA/AI and no official Tolerable Upper Intake Level. Human trials have used 50–250 mg/day, typically split as twice-daily dosing. The blood-pressure effect appeared at the top of that range (125 mg twice daily = 250 mg/day) ^{1Reference 1Riche et al. · 2014RCTAnalysis of pterostilbene on metabolic parameters: a randomized, double-blind, and placebo-controlled trial — [RCT]View study →}, while the same monotherapy dose is where the LDL-cholesterol rise was seen ^{1Reference 1Riche et al. · 2014RCTAnalysis of pterostilbene on metabolic parameters: a randomized, double-blind, and placebo-controlled trial — [RCT]View study →}. In the nicotinamide-riboside combination products, the pterostilbene component is often lower (~100–200 mg/day) ^{3,4Reference 3Dellinger et al. · 2023RCTNicotinamide riboside and pterostilbene reduces markers of hepatic inflammation in NAFLD: a double-blind, placebo-controlled clinical trial — [RCT]View study →Reference 4Jensen et al. · 2022RCTA randomized placebo-controlled trial of nicotinamide riboside and pterostilbene supplementation in experimental muscle injury in elderly individuals — [RCT, null]View study →}. Because pterostilbene is lipophilic, taking it with a fat-containing meal is reasonable, though dedicated food-effect data in humans are limited.

These are doses studied in research, not a personal recommendation.

Safety

Across the human trials to date, pterostilbene has been well tolerated: the dedicated safety analysis of the 80-person metabolic trial found no adverse effects on liver, kidney, or glucose markers and no significant self-reported adverse reactions at up to 250 mg/day over 6–8 weeks ^{2Reference 2Riche et al. · 2013RCTAnalysis of safety from a human clinical trial with pterostilbene — [RCT, safety]View study →}, and the NRPT trials reported good tolerability ^{3,4,5Reference 3Dellinger et al. · 2023RCTNicotinamide riboside and pterostilbene reduces markers of hepatic inflammation in NAFLD: a double-blind, placebo-controlled clinical trial — [RCT]View study →Reference 4Jensen et al. · 2022RCTA randomized placebo-controlled trial of nicotinamide riboside and pterostilbene supplementation in experimental muscle injury in elderly individuals — [RCT, null]View study →Reference 5Simic et al. · 2020RCTNicotinamide riboside with pterostilbene (NRPT) increases NAD⁺ in patients with acute kidney injury — [RCT, safety]View study →}. Reviews consistently note lower toxicity than resveratrol ^{13Reference 13Lin et al. · 2020ReviewOccurrence, bioavailability, anti-inflammatory, and anticancer effects of pterostilbene — [review]View study →}.

The one consistent red flag is lipids: pterostilbene monotherapy raised LDL cholesterol by about 17 mg/dL, an effect that was attenuated when it was combined with grape extract or when the person was already on a cholesterol medication ^{1Reference 1Riche et al. · 2014RCTAnalysis of pterostilbene on metabolic parameters: a randomized, double-blind, and placebo-controlled trial — [RCT]View study →}. Anyone with hyperlipidaemia or on lipid management should factor this in and monitor. Interaction data are sparse; given AMPK/glucose effects and blood-pressure lowering, theoretical additive effects with antidiabetic and antihypertensive drugs are plausible but not formally characterised.

Pregnancy & lactation

Verdict: avoid — not assessed. There are no human pregnancy or lactation safety data for supplemental pterostilbene. Pregnant or breastfeeding people should not take it beyond amounts naturally present in food.

Scope of this safety review (for honesty, not a claim):

• Interactions assessed? Partially — theoretical additive effects with antihypertensive and antidiabetic drugs are noted, but no formal human drug-interaction studies were identified.
• Pregnancy/lactation assessed? No — no human data; treated as “avoid, not assessed.”
• Upper Limit? No official UL exists; well-tolerated to 250 mg/day in short trials, but that is not a safety ceiling and long-term high-dose data are lacking.

References